An overall feel about Emergent BioSolutions Inc. (NYSE: EBS) stock in the current moment?

As of close of business last night, Emergent BioSolutions Inc.’s stock clocked out at $12.05, up 1.77% from its previous closing price of $11.84. In other words, the price has increased by $+0.21 from its previous closing price. On the day, 844955 shares were traded. EBS stock price reached its highest trading level at $12.34 during the session, while it also had its lowest trading level at $11.72.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



To gain a deeper understanding of EBS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.35. For the most recent quarter (mrq), Quick Ratio is recorded 2.10 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.71.

Upgrades & Downgrades

The Benchmark Company Upgraded its Hold to Buy on January 20, 2022, while the target price for the stock was maintained at $77.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 09 when Zoon Kathryn C sold 1,173 shares for $31.52 per share. The transaction valued at 36,973 led to the insider holds 19,654 shares of the business.

Zoon Kathryn C sold 1,996 shares of EBS for $70,918 on May 24. The Director now owns 12,381 shares after completing the transaction at $35.53 per share.

Valuation Measures:

As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.70, and their Forward P/E ratio for the next fiscal year is 15.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 0.41.

Stock Price History:

Over the past 52 weeks, EBS has reached a high of $52.28, while it has fallen to a 52-week low of $11.77. The 50-Day Moving Average of the stock is 19.01, while the 200-Day Moving Average is calculated to be 30.62.

Shares Statistics:

It appears that EBS traded 740.22K shares on average per day over the past three months and 1.43M shares per day over the past ten days. A total of 49.90M shares are outstanding, with a floating share count of 44.81M. Insiders hold about 0.50% of the company’s shares, while institutions hold 84.10% stake in the company. Shares short for EBS as of Oct 13, 2022 were 2.03M with a Short Ratio of 2.16M, compared to 2.05M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.07% and a Short% of Float of 6.45%.

Earnings Estimates

As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of $0.26 and a low estimate of -$0.48, while EPS last year was -$0.36. The consensus estimate for the next quarter is $0.76, with high estimates of $1.06 and low estimates of $0.39.

Analysts are recommending an EPS of between $0.3 and -$0.22 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $2.03, with 5 analysts recommending between $5.39 and $0.54.

Revenue Estimates

In the current quarter, 7 analysts expect revenue to total $268.3M. It ranges from a high estimate of $320M to a low estimate of $247M. As of the current estimate, Emergent BioSolutions Inc.’s year-ago sales were $329M, an estimated decrease of -18.40% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $378.53M, a decrease of -47.70% less than the figure of -$18.40% in the same quarter last year. There is a high estimate of $429M for the next quarter, whereas the lowest estimate is $345M.

A total of 7 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.25B, while the lowest revenue estimate was $1.16B, resulting in an average revenue estimate of $1.2B. In the same quarter a year ago, actual revenue was $1.79B, down -33.20% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.28B and the low estimate is $1.13B. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.